Jun-Ichi Nishimura
Overview
Explore the profile of Jun-Ichi Nishimura including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
1082
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Nishimura J, Kawaguchi T, Ito S, Murai H, Shimono A, Matsuda T, et al.
Int J Hematol
. 2025 Feb;
PMID: 40009332
No abstract available.
2.
Cosson V, Fu R, Kulasekararaj A, Nishimura J, Panse J, Roth A, et al.
Br J Clin Pharmacol
. 2025 Jan;
PMID: 39835421
Aims: Crovalimab is a novel C5 inhibitor administered first intravenously and then subcutaneously in patients with paroxysmal nocturnal haemoglobinuria (PNH) naive to complement inhibition or switching from eculizumab or ravulizumab....
3.
Kulasekararaj A, Kulasekararaj A, Griffin M, Piatek C, Piatek C, Shammo J, et al.
Blood
. 2024 Dec;
145(8):811-822.
PMID: 39700502
Complement C5 inhibitor treatment with ravulizumab or eculizumab for paroxysmal nocturnal hemoglobinuria (PNH) improves outcomes and survival. Some patients remain anemic due to clinically significant extravascular hemolysis (cs-EVH; hemoglobin [Hb]...
4.
Roth A, Kulasekararaj A, Scheinberg P, Nishimura J
Immunotherapy
. 2024 Dec;
16(20-22):1185-1196.
PMID: 39620653
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired, rare, life-threatening hematopoietic stem cell disorder that causes stem cell-derived cells to be vulnerable to complement-mediated lysis and manifests as hemolytic anemia, thrombosis,...
5.
Miyakawa Y, Sato E, Ogawa Y, Nishimura J, Nishimi M, Kawaguchi O, et al.
Int J Hematol
. 2024 Oct;
120(6):656-664.
PMID: 39402301
Sutimlimab, a complement inhibitor, has recently been approved in Japan for treating cold agglutinin disease (CAD). We report the safety and efficacy of sutimlimab in Japanese patients with CAD who...
6.
Szer J, Panse J, Kulasekararaj A, Oliver M, Fattizzo B, Nishimura J, et al.
Int J Mol Sci
. 2024 Aug;
25(16).
PMID: 39201278
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, potentially life-threatening haematological disease characterised by chronic complement-mediated haemolysis with multiple clinical consequences that impair quality of life. This post hoc analysis assessed...
7.
Roth A, Berentsen S, Barcellini W, DSa S, Jilma B, Michel M, et al.
EClinicalMedicine
. 2024 Aug;
74:102733.
PMID: 39091672
Background: Cold agglutinin disease (CAD) is a rare autoimmune haemolytic anaemia mediated by the classical complement pathway (CP). Sutimlimab selectively targets complement C1s inhibiting classical CP activation. In CADENZA Part...
8.
Roth A, He G, Tong H, Lin Z, Wang X, Chai-Adisaksopha C, et al.
Am J Hematol
. 2024 Jun;
99(9):1768-1777.
PMID: 38884175
Crovalimab is a novel C5 complement inhibitor that enables rapid and sustained C5 inhibition with subcutaneous, low-volume self-administration every 4 weeks. COMMODORE 2 (NCT04434092) is a global, randomized, open-label, multicenter,...
9.
Lee J, Griffin M, Kim J, Lee L, Piatek C, Nishimura J, et al.
Lancet Haematol
. 2023 Nov;
10(12):e955-e965.
PMID: 38030318
Background: Symptoms of anaemia due to clinically significant extravascular haemolysis can affect patients with paroxysmal nocturnal haemoglobinuria (PNH) treated with C5 inhibitors (ravulizumab or eculizumab). The aim of this study...
10.
Nishimura J
Rinsho Ketsueki
. 2023 Oct;
64(9):884-891.
PMID: 37793862
In recent years, it has become clear that various diseases are caused by complement (related molecule) abnormalities (complementopathies) or are exacerbated by complement (complement-related diseases), and novel therapeutic agents targeting...